
Know

- Sotrovimab has been added as an EUA treatment of mild to moderate COVID-19 positive patients meeting EUA criteria. It is only available for IV administration and is not approved for post-exposure prophylaxis. All administration instructions will be included in the ERX orders. Monitor the patient for 1 hour after infusion is complete.
- Effective 1/6/2022, given the rise of the Omicron variant, Casirivimab / Imdevimab or Bamlanivimab/Etesevimab will no longer be available for treatment or post-exposure prophylaxis of COVID-19.
- Although historically only administered by Oncology-trained nurses, the Oncology Nurses Society guidelines state all RNs can safety administer COVID antibody therapy if they receive training and education and are supported with PRN orders in case of patient adverse reactions to the therapy.
- Nursing, Pharmacy, and Providers have worked together to develop the following structure for success:
  - **Nursing Policy**: Administration of EUA/FDA-Approved Therapy for COVID Indications
  - **Education & Training**: C20386 – Administration of EUA/FDA-Approved Therapy for COVID Indications
  - **COVID-19 ANTIBODY INFUSION REACTION TREATMENT** Panel has been created as companion to the medication order, in case of mild, moderate, or severe infusion reaction symptoms.

Do

- Work with local Providers, Pharmacy, and Nurse leaders to discuss the approval and operations needed to be able to provide this best practice treatment to our patients who meet criteria.
  - Follow local clinical policy approval process
  - Assign eLearning course to selected RNs, per affiliate determination
  - Go-live when affiliate determines

Share

- This KDS education and information with all nurse educators and RNs who may be administering sotrovimab
- For more information, please select the links below:

  **Sotrovimab Fact Sheet for Health Care Providers**

For questions or concerns, please contact nursing education or management.